The ⑀4 allele of APOE is generally accepted to be a risk factor in Alzheimer's disease and it has been related to other neuropsychiatric disorders, including schizophrenia. The results of several case-control studies have been inconclusive. To shed more light on this issue we carried out an association study that compared the APOE common variant in a group of 365 schizophrenia patients and 584 controls. We found no differences in the genotype distributions and allele frequencies of patients and controls. In the group of patients, we also analysed the possible influence of the ⑀4 allele in the clinical variables. The most important findings are that the age at onset (AAO) of ⑀4+ schizophrenic women, those that have one or two ⑀4 alleles, is 4 years earlier than that of ⑀4− women and their risk of suffering a negative syndrome subtype is four times greater. This was not found in schizophrenic men. Our results show that the APOE variant is not a risk factor for developing schizophrenia but that it may modulate its phenotypic expression in a sex-dependent manner. Molecular Psychiatry (2001) 6, 307-310.
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Apolipoprotein E (ApoE) is a lipophilic peptide present in plasma lipoproteins and several tissues and body fluids, where it has a major role in the redistribution of lipids among cells. In the general population ApoE exists as three common isoforms (E2, E3 and E4) encoded by three different alleles (⑀2, ⑀3 and ⑀4). It is synthesized first and foremost in the liver, followed by the brain, 1,2 where its expression is upregulated after insults 2 and by estrogens. 3, 4 It is currently accepted that the ⑀4 allele is a risk factor in Alzheimer's disease (AD) and that it determines an earlier development of the disease in a dosedependent manner. 5, 6 Nevertheless, the presence of an ⑀4 allele is neither sufficient nor necessary for the development of AD and its role in the neuropathology of this disorder and in other neuropsychiatric illnesses, including schizophrenia, remains unclear.
Schizophrenia is a complex psychiatric disorder in which a genetic component is accepted. Many candidate genes, including APOE, have been chosen for association studies in schizophrenia. Harrington et al 7 were the first to report an increased frequency of the ⑀4 allele in schizophrenic patients. However, subsequent studies in other populations have failed to replicate this finding. [8] [9] [10] [11] [12] [13] [14] [15] [16] Apart from these controversial results, it is interesting to note that some of the studies that found no association between APOE variants and the disease, did find an association with clinical variables such as age at onset 10, 17 and scores for psychotic symptoms. 18, 19 To further ascertain the possible association between the APOE variant and schizophrenia, and to determine whether the ⑀4 allele may modulate the clinical variables of patients, we have addressed this issue in a large sample of schizophrenic in-patients.
The APOE genotype distribution of both patients and controls did not deviate from the Hardy-Weinberg equilibrium. The allele and genotype frequencies (Table 1) were similar in both groups. Therefore, we rejected the hypothesis that the APOE genotype could be a risk factor for schizophrenia in our sample. This is not in accordance with the findings of Harrington et al, 7 who reported increased frequency of the ⑀4 allele in Caucasian schizophrenic patients. Neither is it in accordance with a recent report by Chen et al, 16 who showed an association between the ⑀3 allele and schizophrenia patients from Asia. However, several case-control association studies have found no association between the APOE genotype and schizophrenia. [8] [9] [10] [11] [12] [13] [14] [15] The inconsistency in these data may be due to several factors; the samples may be too small, there may be problems of sample stratification, the cases and controls may not be correctly matched, and there may be ethnic differences.
The second hypothesis was that the ⑀4 allele may modulate the clinical variables. To determine whether this is so, an association analysis was performed. For this purpose, the patients were put into two groups: those with one or two ⑀4 alleles (⑀4+) and those with none (⑀4−). The regression analysis showed that the ⑀4 allele was significantly associated to AAO and sex. The AAO of men is, on average, 16% less than that of women (mean (SD): 23.5 (7.1) years vs 26.9 (10.0) years, respectively, P = 0.0001). This result had been expected because an earlier AAO in men is one of the most robust gender differences observed worldwide. 20 To analyse the effect of the ⑀4 allele on AAO, the sample was therefore stratified by gender. In this case, ⑀4+ women have a 15% lower AAO (P = 0.03) ( Table  2 ) than ⑀4− women. Conversely, men with the ⑀4 allele have similar AAO (3.7% higher, P Ͼ 0.05) than those without. In fact, the mean AAO in ⑀4+ women is 23.4 (5.6) and 27.7 (10.7) in ⑀4− women, while in men the means are similar for both groups (23.4 (7.1) for ⑀4+ and 23.5 (8.0) for ⑀4−).
We have also found statistically significant differences in the syndrome subtype of men and women. ⑀4+ women have a greater risk of developing negative rather than positive syndrome subtype than ⑀4− women ( Table 2 ). The odds ratio is about 4 (P = 0.003) in simple regression analysis and almost 3 (P = 0.05) in multiple regression analysis, which was adjusted for AAO, FH, onset type, and the interaction between the ⑀4 allele and AAO. In the male group we found no differences in the risk of developing negative or positive syndrome subtypes between those with the ⑀4 allele and those without. Statistically significant association between the ⑀4 allele and earlier AAO has already been reported. 10 Although we have not measured the positive symptoms, our results are in accordance with other studies 18, 19 that found that the positive symptoms of patients with the APOE ⑀4 allele are less severe than those of patients without it.
In schizophrenia, gender differences have been reported in terms of AAO, incidence, course, premorbid adjustment, symptomatology and clinical presentation, structural brain abnormalities, family history, history of obstetric complications in patients' mothers and foetal exposure to maternal influenza (reviewed in Salem and Kring 20 ) . One of the factors that may contribute to some of the gender differences in schizophrenia is the estrogen level. Clinical observations show a strong negative correlation between the estrogen level and psychotic symptoms. 20 As a result several researchers believe that estrogen hormones have antipsychotic effects. Likewise, estrogen may help delay AAO in women. Similar results with estrogen have been observed in Alzheimer's disease, 21, 22 where APOE is a robust risk factor.
Recent reports have demonstrated that in rodents estrogen increases the expression of apoE mRNA in specific areas of the brain. 3, 4 However, the specific role of apoE in the brain and the functional differences between the three common variants (E2, E3 and E4) are still unknown. To explore this issue further, Raber et al 23 analysed apoE transgenic mice that expressed similar levels of human apoE3 or E4 in the brain. Interestingly, they found that the E4 females had significantly impaired learning, memory and exploratory behaviour compared to males or E3 mice. The authors claimed that these results may be related to the greater susceptibility to AD associated with the APOE ⑀4 allele, which is stronger in females. Here we argue that, although APOE is not a risk factor in the development of schizophrenia, it may modulate its phenotypic expression and this influence is stronger in women. This is an issue that needs to be explored.
Methods

Subjects
We studied 365 unrelated schizophrenic in-patients (222 males and 143 females, mean age 56.9 (16.3) years, range 19-90 years), and 584 control subjects (366 males and 218 females, mean age 52.2 (18.5) years, range 19-97 years). All patients were diagnosed with schizophrenia according to ICD-9 criteria and treated at the Hospital Psiquiàtric Universitari Institut Pere Mata in Reus, Spain. A detailed family history of psychiatric illness was obtained from each patient and at least one of their unaffected relatives. Control subjects were selected from the same geographical area and had no psychiatric or neurological disorder. Both groups had similar ethnic backgrounds (European-Caucasian). The study was made in accordance with the ethical guidelines of our local Medical Ethical Committee and informed consent was obtained from patients and controls after full explanation of the procedures.
Variables studied
All variables were taken from the clinical records of information obtained from patients, family members and caregivers. To facilitate statistical analysis the clinical variables that contained more than two categories were clustered into two subsets according to Valero et al. 24 Briefly, schizophrenia subtypes (on ICD-9 classification) were grouped as positive symptom syndrome-like or negative symptom syndrome-like (the new variable is called 'syndrome subtype') according to the Association for Methodology and Documentation in Psychiatry (AMDP) scale system, 25 which we use in our clinical records. Course of illness was divided into two sets: one containing the episodic subtypes (unique or multiplex) and the other containing the chronic, continuous subtypes. Onset type was defined as acute or insidious. Family history (FH) was defined as FH(+) for patients with a first or second degree relative with schizophrenia, schizoaffective or delusional disorders and FH(−) for sporadic cases. Non-informed cases were excluded from the analysis. Age at onset (AAO) was defined as the age at which the first prominent psychotic symptom (congruent with ICD-9 criteria) had been noted.
Molecular Psychiatry
APOE genotyping DNA samples were extracted from peripheral blood and APOE genotypes were obtained as described elsewhere. 26 APOE genotypes were scored independently by two observers who were blind to the diagnostic status of the subject and the allele frequencies were estimated by gene counting for each group.
Statistical evaluation
(1) Case-control association analysis The genotype distribution and Hardy-Weinberg equilibrium were tested using the chi-square test. The allele frequencies of patients and controls and of the different subgroups of patients were compared by the CLUMP program using the Monte Carlo approach. 27 (2) Association analysis between the APOE ⑀4 allele and the clinical variables APOE genotypes were grouped in ⑀4+ (for individuals with one or two ⑀4 alleles) and ⑀4− for the others. The AAO distribution was negatively skewed (Kolmogorov-Smirnoff test, D = 0.152, P = 0.001) and therefore log-transformed to fit into a Gaussian distribution. Mean AAO between men and women in the whole sample were compared by the ANOVA.
Multiple and simple regressions were used to analyse how having or not having an ⑀4 allele affects the clinical variables. Logistic regression was used to evaluate the probability of having an insidious or acute onset, a chronic or episodic course and a negative or positive syndrome subtype. The effect of AAO on all clinical variables was assessed using lineal regressions. Gender was used to stratify the sample in all regressions, and gender plus family history was used in the multiple ones. Onset type, syndrome subtype, AAO (over 33 years old and less than or equal to 33 years old, based on the inflexion point of the AAO histogram) and the interactions of the ⑀4 allele with some of these variables were also used to adjust, in some cases, the multiple regression analysis. The odds ratio (OR) with the corresponding confidence interval (CI) was used as a measure of association for logistic regressions and percentual increments (% ⌬) with the corresponding P-value for lineal regressions. All tests were two-tailed and significance was accepted at P Ͻ 0.05. SAS 8.0 was used for the statistical analysis unless otherwise stated.
